您的位置：首页 > 论文页面
PD-1/PD-L1阻断剂的临床研究进展
发表时间：2018-09-14 浏览量：2196 下载量：374
| 全部作者： | 葛驾，张发明 |
| 作者单位： | 武汉大学药学院 |
| 摘 要： | 程序性细胞死亡蛋白1（programmed cell death protein 1，PD-1）是一种抑制性免疫受体，它通过与配体PD-L1和PD-L2结合，抑制T细胞的增殖及其介导的免疫应答。阻断PD-1/PD-L1信号通路能够逆转这一过程，从而增强抗肿瘤免疫活性。目前，已经成功开发了通过增强T细胞功能来阻断PD-1/PD-L1途径的单克隆抗体（monoclonal antibodies，mAbs）用于癌症免疫治疗。临床研究表明，PD-1/PD-L1阻断剂临床试验显示出非常高的响应率，特别是对于黑色素瘤、非小细胞肺癌、肾细胞癌和膀胱癌。PD-1/PD-L1阻断剂联合疗法能改善自身的不足，并正在广泛研究之中。本文旨在总结与展望PD-1/PD-L1阻断剂的临床研究情况。 |
| 关 键 词： | 生物药物学；肿瘤；综述；程序性细胞死亡蛋白1（PD-1）；程序性细胞死亡蛋白配体1（PD-L1）；免疫治疗 |
| Title： | Clinical research progress of PD-1/PD-L1 blockade agents |
| Author： | GE Jia, ZHANG Faming |
| Organization： | School of Pharmaceutical Sciences, Wuhan University |
| Abstract： | Programmed cell death protein 1 (PD-1) is an inhibitory immune receptor, which inhibits T cell proliferation and its mediated immune response by binding to its ligands, PD-L1 and PD-L2. Blocking the PD-1/PD-L1 signaling pathway can reverse this process and enhance antitumor immunity. Monoclonal antibodies (mAbs) that block the PD-1/PD-L1 pathway by enhancing T cell function have been developed for cancer immunotherapy. Clinical trials with PD-1/PD-L1 blockade angents have shown impressive response rates in patients, especially for melanoma, non-small-cell lung cancer, renal cell carcinoma and bladder cancer. PD-1/PD-L1 blockade angents combination therapies which can improve its own deficiency are being extensively studied. This paper aims to summarize and prospect the clinical study of PD-1/PD-L1 blockade angents. |
| Key words： | biopharmaceutics; cancer; review; programmed cell death protein 1 (PD-1); programmed cell death protein ligand 1 (PD-L1); immunotherapy |
| 发表期数： | 2018年9月第17期 |
| 引用格式： | 葛驾，张发明. PD-1/PD-L1阻断剂的临床研究进展[J]. 中国科技论文在线精品论文，2018，11（17）：1734-1741. |
2
评论数 0请您登录
暂无评论
下载全文
多维论文